Innocoll AG

Innocoll — Investor Presentation (September 2015)

37 slides from Innocoll's investor presentation, Sep 21, 2015

  1. Slide 1: Corporate Presentation September 2015

    Corporate Presentation September 2015 MAKING BETTER HAPPEN

  2. Slide 2: Forward Looking Statements

    2 l Forward Looking Statements Any statements in this presentation about our future expectations, plans and prospects, including statements about the development of our product candidates and the timing, conduct, enrollment and outcome of our clinical studies, the availability of data from those stu

  3. Slide 3: September 2015 Update

    3 l September 2015 Update COGENZIA: QIDP FDA designation – Accelerates pre - commercialization efforts COGENZIA: Phase 3 program initiated in May XARACOLL: Phase 3 program initiated in August Executive Team bolstered – Pepe Carmona, CFO – Rich Fante, CCO

  4. Slide 4: What if we could consistently make medicines work better?

    4 l “What if we could consistently make medicines work better?” At Innocoll, every day we ask ourselves

  5. Slide 5: Innocoll Engineering: collagen-based drug delivery

    5 l Products can be easily manipulated for : Surgical implantation including open and laparoscopic placement Topical application to open wounds Innocoll Engineering H i gh l y pu rifie d T y pe 1 c oll a g e n API + Film , m atrix, g el Extensive experience of collagen bioprocessing Ability to contr

  6. Slide 6: Late-stage Therapeutic Products

    6 l 3 Late - stage* Therapeutic Products Reduction of surgical adhesions * These products have not been approved by FDA, and therefore, the FDA has not determined their safety and effectiveness for commercial marketing and sale . Diabetic foot ulcer infection (DFI) treatment Post - operative pain

  7. Slide 7: What if a new method of surgical pain management could provide more comfort?

    7 l “What if a new method of surgical pain management could provide more post - operative patient comfort?”

  8. Slide 8: XARACOLL: A New Candidate to Treat Pain

    8 l XARACOLL A New Candidate to Treat Pain A resorbable, implantable collagen matrix with bupivacaine for management of post - surgical pain Engineered to provide sustained local analgesia at the surgical site Can be used in both open and laparoscopic surgery Designed to provide up to 72 hours of po

  9. Slide 9: Post-operative Pain Management

    9 l Post - operative Pain Management Opioids The standard of care for post - operative pain includes administration of systemically acting μ - opioid agonists including morphine Two areas of greatest unmet need in the treatment of postoperative pain: – Lowering postoperative opioid consumption – red

  10. Slide 10: US Surgical Procedures Considered

    10 l US Surgical Procedures Considered * *XARACOLL MATRIX - 1 and MATRIX - 2 Phase 3 studies are in open hernia repair. ** Cofactor Group March 2015 analysis on behalf of Innocoll US Surgical Procedures Approximately 70M Specific Procedures Considered • General • OB/GYN • Cosmetic • Orthopedic • Bac

  11. Slide 11: XARACOLL: Phase 2 Hernia Study Results Summary

    11 l XARACOLL: Phase 2 Hernia Study Results Summary Integrated Endpoint of Pain Intensity and Opioid Consumption Observed Treatment Effect vs Placebo Control Integrated Pain Intensity/ Opioid Consumption 100 mg trial (n=53) P - value 200 mg trial (n=50) P - value 24 hours 0.013* 0.005* 48 hours 0.09

  12. Slide 12: XARACOLL: Phase 3 Program

    12 l XARACOLL: Phase 3 Program Three Phase 3 Studies Open Hernioplasty: Ongoing Objective Dose(s) No. Patients Primary Endpoint Data Available (estimate) PK & Safety vs . Bupivacaine Infiltration (study completed) 200 mg & 300 mg 60 PK 2015 Efficacy & Safety vs . Placebo 300 mg 300 Sum of Pain Inten

  13. Slide 13: Target Profile for XARACOLL USA

    13 l Target Profile for XARACOLL USA * TPP Components PRODUCT DESCRIPTION • XARACOLL ® (bupivacaine - collagen bioresorbable implant) is a perioperative surgical implant that delivers bupivacaine hydrochloride to provide sustained local analgesia INDICATION • Indicated for single dose administration

  14. Slide 14: XARACOLL: Market Research Findings

    14 l XARACOLL: Market Research Findings* While all surgeons indicate that post - operative pain is one of their top concerns entering any procedure, the need for aggressive post - operative pain management differs by procedure type Legacy products do not fully meet the needs of physicians and patien

  15. Slide 15: What if diabetic foot ulcer infection rates could be reduced?

    15 l “What if diabetic foot ulcer infection rates — a major factor in amputations — could be reduced with local adjuvant therapy?”

  16. Slide 16: COGENZIA

    16 l COGENZIA A resorbable, topical collagen matrix with gentamicin for treatment of DFIs ( diabetic foot infections) Engineered to provide broad antibacterial efficacy at the wound site Has potential to reduce amputations in diabetic patients Received QIDP designation Q2 2015 – Potential fast track

  17. Slide 17: DFI Market

    17 l DFI Market * 15.7 million patients globally have DFI S tandard of care has a 30%+ failure rate Currently, there are no approved topical antibiotics indicated to treat DFIs T2D Prevalence: CDC: Diabetes National Surveillance Data, October 2014 – using the 5 year CAGR 2007 to 2011 DFU Prevalence:

  18. Slide 18: Opportunity: DFU/DFIs among top complications for diabetic patients

    18 l HEART DISEASE AND STROKE KIDNEY FAILURE Opportunity: DFU/DFIs among the top complications for diabetic patients Source: S takeholder interviews on behalf of Innocoll , Jul - Aug’15; National diabetes statistics report, 2014; International Diabetes Federation. ~60% of non - traumatic lower limb

  19. Slide 19: COGENZIA: Phase 2 Studies

    19 l COGENZIA: Phase 2 Studies COGENZIA demonstrated a statistically significant increase in the rate of clinical cure (100% vs 70%) despite larger ulcers and more severe wound scores at baseline 100% pathogen eradication achieved with COGENZIA vs. 62 % for control; statistically significant at ever

  20. Slide 20: COGENZIA: Phase 3 Study Design

    20 l COGENZIA: Phase 3 Study Design Treatment Period / Visits up to 28 days Treatment ( n=250) COGENZIA plus systemic antibiotic therapy & standard wound care Day 7 Day 14 Day 21 Day 28 Day 1 PRIMARY ENDPOINT: % Patients achieving “Clinical Cure” at Test - of - Cure STATISTICAL POWER: 85% (assuming

  21. Slide 21: Target Profile for COGENZIA USA

    21 l Target Profile for COGENZIA USA * TPP Components INDICATION: US Indicated for the treatment of infected foot ulcers in diabetic patients in combination with systemic antibiotics EFFICACY When studied in large - scale Phase III clinical programs, Cogenzia, when used in combination with systemic

  22. Slide 22: COGENZIA Profile Market Research

    22 l Profile Market Research Very positive about a topical product that delivers a high concentration of antibiotic to the site of the infection Profile concerns related to: Difficulties changing dressings due to obesity and decreased dexterity Requested information about the amount of systemic abso

  23. Slide 23: COGENZIA: QIDP FDA Designation

    23 l COGENZIA: QIDP FDA Designation Accelerates pre - commercialization efforts 2016 2015 2017 Q3 16 * : COGENZIA US Phase 3 Data Dec’16 * : FDA COGENZIA Submission Jul’17 ** : US COGENZIA Approval Jun’15: QIDP Designation for COGENZIA * estimated ** estimated, assumes Fast - Track designation

  24. Slide 24: What if one simple step could reduce post-operative adhesions?

    24 l “What if one simple step could significantly reduce the incidence and extent of post - operative adhesions?”

  25. Slide 25: COLLAGUARD

    25 l COLLAGUARD Bioresorbable collagen film implanted during surgery Designed to serve as a temporary barrier to separate apposing adhesiogenic surfaces during tissue repair Approved in multiple ROW markets based on animal data – Increased probability of remaining adhesion free by >6 - fold – Reduce

  26. Slide 26: Adhesion Barrier Market

    26 l Adhesion Barrier Market Adhesion barriers are used prophylactically to reduce abnormal internal scarring and adhesions following surgery and are used for multiple procedure types Current use of adhesion barriers is low with good opportunities for growth * Cofactor Group March 2015 analysis on b

  27. Slide 27: Target Profile for COLLAGUARD USA

    27 l Target Profile for COLLAGUARD USA * TPP Components INDICATION: US • COLLAGUARD is indicated as an adjunct to good surgical technique to reduce the incidence, extent and severity of post - operative adhesions in digestive, colorectal, gynecological, and urological surgeries, including both open

  28. Slide 28: COLLAGUARD Market Research Findings

    28 l COLLAGUARD Market Research Findings Moderate - to - high level concern for post - operative adhesion development Concern relates to future patient complications and preservation of future surgical fields Dissatisfaction with currently marketed adhesion barrier product as related to handling and

  29. Slide 29: Promising Clinical Studies

    29 l Promising Clinical Studies In animal studies, COLLAGUARD increased the probability of remaining adhesion - free by more than six - fold and significantly reduced the extent and severity of adhesions COLLAGUARD is ready to enter a pivotal study once details of the study are worked out with FDA

  30. Slide 30: Clinical Development Timelines

    30 l Clinical Development Timelines * 2015 2016 2017 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q COGENZIA COACT - 1 (US) COACT - 2 (EU/US) XARACOLL CB - 013 PK MATRIX 1 MATRIX 2 CG - 001 CG US Development Enrollment Topline Data FSFV FDA Submission FDA Approval * estimated

  31. Slide 31: Our Strategy: Leverage, Expand, Execute

    31 l Our Strategy LEVERAGE EXPAND EXECUTE

  32. Slide 32: Our Strategy — Leverage and Expand

    32 l Our Strategy — Leverage and Expand Areas under consideration for further investment Opportunity A nti - infectives Pain management New Therapeutic Areas Opportunity Examples G eographic expansion • XARACOLL EU • COLLAGUARD US LCM XARACOLL • Orthopedic surgery • Laparoscopic surgery LEVERAGE EXP

  33. Slide 33: Experienced Management Team

    33 l Experienced Management Team Name Position Exp. Key Companies Anthony Zook President & CEO 30 yrs Jose (Pepe) Carmona Chief Financial Officer 20 yrs Michael Myers Ph.D. Head of Portfolio Operations 28 yrs Rich Fante Chief Commercial Officer & Head of Business Development 25 yrs James Croke EVP E

  34. Slide 34: Directed by Industry Leaders

    34 l Directed by Industry Leaders Name Credentials Jon Symonds Chairman • Former CFO Novartis • Former CFO AstraZeneca Shumeet Banerji • Board of Directors of Hewlett Packard • Former CEO of Booz and Company David Brennan • Former CEO of AstraZeneca • Board Member Alexion, Insmed • Former PhRMA Boar

  35. Slide 35: Innocoll built healthy cash flow from IPO, follow-on and bank loan

    35 l Innocoll built a healthy cash flow from IPO, follow - on and bank loan to prepare for a global commercial stage Cash and Cash equivalents at the end of the period in Million Euros Sources of Cash IPO $ 54.4 Mio EIB € 25.0 Mio Follow - On $ 16.1 Mio

  36. Slide 36: Accelerating commercial stage ramp-up requires investment

    36 l Accelerating commercial stage ramp - up requires investment in R&D, Manufacturing and Commercial Clinical program XARACOLL Pre - launch Q4 15 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Funded Non funded (1) Clinical program COGENZIA Pre - launch Clinical Pilot COLLAGUARD Clinical Program Building and

  37. Slide 37: September 2015 Update

    37 l September 2015 Update COGENZIA: QIDP FDA designation – Necessitates accelerated pre - commercialization efforts COGENZIA: Phase 3 program initiated in May XARACOLL: Phase 3 program initiated in August

Innocoll — Investor Presentation (September 2015) on 6ix